Detalhe da pesquisa
1.
A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice.
Oncologist
; 2024 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38642091
2.
Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.
Cancer Immunol Immunother
; 73(7): 119, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713205
3.
Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.
J Pharmacol Exp Ther
; 388(1): 156-170, 2024 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37918855
4.
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Haematologica
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38235512
5.
Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib.
Chin J Cancer Res
; 35(5): 526-535, 2023 Oct 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37969958
6.
Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers.
Oncologist
; 2022 Apr 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445725
7.
A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer.
Cancer
; 127(21): 3975-3984, 2021 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34355801
8.
Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III trial.
Future Oncol
; 17(11): 1339-1350, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33325251
9.
Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(11): 1489-1499, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966810
10.
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet Oncol
; 21(11): 1500-1512, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966811
11.
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial.
JAMA
; 319(24): 2486-2496, 2018 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29946728
12.
Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.
ACS Med Chem Lett
; 15(5): 595-601, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38746892
13.
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.
Eur J Cancer
; 199: 113539, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38237373
14.
Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases.
Eur J Cancer
; 181: 26-37, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36628898
15.
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study.
Lancet Haematol
; 10(6): e406-e418, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37028433
16.
S100A8 accelerates wound healing by promoting adipose stem cell proliferation and suppressing inflammation.
Regen Ther
; 21: 166-174, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35891712
17.
Study on the Mechanical and Toughness Behavior of Epoxy Nano-Composites with Zero-Dimensional and Two-Dimensional Nano-Fillers.
Polymers (Basel)
; 14(17)2022 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36080694
18.
Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study.
Clin Lung Cancer
; 23(6): e353-e361, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35654732
19.
Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep).
Eur J Cancer
; 169: 1-9, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489301
20.
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations.
JTO Clin Res Rep
; 3(10): 100407, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36217329